牛磺酸上调基因1在弥漫性大B细胞淋巴瘤患者中的表达及其与预后的关系

发布时间：2018-05-18 22:44

本文选题：弥漫性大B细胞淋巴瘤 + 牛磺酸上调基因　；参考：《中国肿瘤生物治疗杂志》2017年11期

【摘要】：目的:探讨牛磺酸上调基因1(taurine upregulated gene 1,TUG1)在弥漫性大B细胞淋巴瘤(diffuse large B-cell Lymphoma,DLBCL)患者组织标本中的表达,分析TUG1表达与DLBCL患者临床特征及其预后的关系。方法:收集108例2011年1月至2016年12月在西南医科大学附属第一医院血液科确诊为DLBCL的初诊患者和同期47例反应性淋巴结增生(reactive lymphoid hyperplasia,RLH)患者的组织标本,通过q PCR方法检测DLBCL和RLH患者组织标本中TUG1的表达,采用Chi-Square检验、Kaplan-Meier法和单因素及多因素分析法分别分析TUG1 mRNA表达水平与DLBCL患者临床病理特征的关系和影响DLBCL患者生存时间及预后的因素。结果:TUG1 mRNA在DLBCL患者组织中的表达显著高于RLH患者(6.108±0.332 vs 1.231±0.095,P0.01),TUG1 mRNA表达与DLBCL患者的疾病分期、肿瘤大小、B细胞症状、IPI指数、GCB亚型及化疗敏感性显著相关(均P0.01),TUG1表达量、疾病分期及肿瘤大小是影响DLBCL患者总生存时间(overall survival,OS)的因素。TUG1 mRNA表达、疾病分期、IPI指数和化疗敏感性是影响DLBCL患者预后的因素。结论:TUG1 mRNA在DLBCL组织中高表达,是影响患者预后的独立因素,TUG1有可能成为DLBCL患者新的预后评估标志物和基因治疗DLBCL的潜在靶点。
[Abstract]:Objective: to investigate the expression of taurine upregulated gene 1(taurine upregulated gene 1 (TUG1) in patients with diffuse large B-cell lymphoma (DLBCL) and to analyze the relationship between the expression of TUG1 and the clinical features and prognosis of patients with DLBCL. Methods: tissue specimens were collected from 108 newly diagnosed patients with DLBCL from January 2011 to December 2016 in the Department of Hematology, first affiliated Hospital of Southwest Medical University, and 47 patients with reactive lymphoid hyperplasia from the same period. The expression of TUG1 in tissues of patients with DLBCL and RLH was detected by Q PCR method. Kaplan-Meier method and univariate and multivariate analysis were used to analyze the relationship between the expression of TUG1 mRNA and clinicopathological features of DLBCL patients and the factors influencing the survival time and prognosis of DLBCL patients. Results the expression of TUG1 mRNA in patients with DLBCL was significantly higher than that in patients with RLH (6.108 卤0.332 vs 1.231 卤0.095). The expression of TUG1 mRNA in patients with DLBCL was significantly correlated with the stage of the disease, the tumor size and B cell symptom and the expression of DLBCL subtype and chemosensitivity (all P0.01and TUG1). Disease stage and tumor size were the factors influencing the overall survival time of DLBCL patients. The expression of TUG1 mRNA was the main factor affecting the prognosis of DLBCL patients. Conclusion the high expression of TUG1 mRNA in DLBCL tissues is an independent factor affecting the prognosis of DLBCL patients. TUG1 may be a new prognostic marker for DLBCL patients and a potential target for DLBCL gene therapy.
【作者单位】：西南医科大学附属第一医院血液科;
【分类号】：R733

【相似文献】